INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
INO$1.45-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
| Preferred stock · Common stock · Additionalpaid-incapital · Accumulateddeficit · Accumulatedothercomprehensiveloss · Totalstockholders’equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Numberof shares · Amount · Numberof shares · Amount | ||||||||
| Balance at December 31, 2023 | 9 | $— | 22,793,075 | $22,792 | $1,740,954,074 | $(1,622,965,136) | $(662,601) | $117,349,129 |
| Issuance of common stock for cash, net of financing costs | — | — | 13,213,778 | 13,214 | 36,020,259 | — | — | 36,033,473 |
| Issuance of pre-funded warrants for cash, net of financing costs | — | — | — | — | 16,146,397 | — | — | 16,146,397 |
| Exercise of stock options for cash and vesting of RSUs, net of tax payments | — | — | 93,138 | 93 | (353,213) | — | — | (353,120) |
| Stock-based compensation | — | — | — | — | 6,595,108 | — | — | 6,595,108 |
| Net loss | — | — | — | — | — | (107,254,126) | — | (107,254,126) |
| Unrealized loss on short-term investments, net of tax | — | — | — | — | — | — | (45,469) | (45,469) |
| Foreign currency translation | — | — | — | — | — | — | 32,403 | 32,403 |
| Balance at December 31, 2024 | 9 | $— | 36,099,991 | $36,099 | $1,799,362,625 | $(1,730,219,262) | $(675,667) | $68,503,795 |
| Issuance of common stock for cash, net of financing costs | — | — | 29,936,085 | 29,937 | 34,878,656 | — | — | 34,908,593 |
| Exercise of warrants for cash | — | — | 721,427 | 722 | 1,261,775 | — | — | 1,262,497 |
| Exercise of pre-funded warrants for cash | — | — | 2,135,477 | 2,135 | — | — | — | 2,135 |
| Change in classification of warrants from liability to equity due to exercise | — | — | — | — | 681,625 | — | — | 681,625 |
| Exercise of stock options for cash and vesting of RSUs, net of tax payments | — | — | 103,667 | 104 | (110,064) | — | — | (109,960) |
| Stock-based compensation | — | — | — | — | 3,755,788 | — | — | 3,755,788 |
| Net loss | — | — | — | — | — | (84,945,901) | — | (84,945,901) |
| Unrealized gain on short-term investments, net of tax | — | — | — | — | — | — | 37,704 | 37,704 |
| Balance at December 31, 2025 | 9 | $— | 68,996,647 | $68,997 | $1,839,830,405 | $(1,815,165,163) | $(637,963) | $24,096,276 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.